{"id":"NCT03623243","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients","officialTitle":"Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-14","primaryCompletion":"2022-07-06","completion":"2022-07-06","firstPosted":"2018-08-09","resultsPosted":"2023-07-20","lastUpdate":"2024-06-20"},"enrollment":185,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Relapsing Multiple Sclerosis","Advancing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Siponimod","otherNames":["BAF312"]}],"arms":[{"label":"Siponimod","type":"EXPERIMENTAL"}],"summary":"To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.","primaryOutcome":{"measure":"Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) Related to Study Drug During the Treatment Period","timeFrame":"From first dose of study drug up to 30 days after last dose of study drug (up to 7 months)","effectByArm":[{"arm":"Siponimod","deltaMin":59,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":55,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["40248858"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1555"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":185},"commonTop":["Headache","Urinary tract infection","Nausea","Fatigue","Dizziness"]}}